Treatment
Fdg clinical trials
We’re tracking 153 recruiting studies that include Fdg, each written for real people, not researchers, below.
Recruiting studies
- NCT06814587Recruiting
New imaging for heart muscle damage after a heart attack
This study uses special imaging scans (MRI and PET) to look at the health of the heart muscle in people with advanced heart failure caused by blocked arteries. The goal is to better predict recovery after bypass surgery.
Dallas, TexasAges 20–80 - NCT06834412Recruiting
New PET scan for blood cancer staging
This study tests a new type of PET scan called 68Ga-Pentixafor to see how well it finds and stages blood cancers (like non-Hodgkin lymphoma and myeloma). It will compare this new scan to the standard FDG-PET scan. If you join, you may get more accurate information about your cancer.
Xi'an, ShaanxiAges 18–75 - NCT06877949Recruiting
PET/CT vs. CT Scan for Monitoring Metastatic Breast Cancer
This trial compares two types of scans (PET/CT and CT) to see which is better at monitoring metastatic breast cancer. If you are starting your first treatment for breast cancer that has spread to other parts of the body, this study may help determine the best way to track your disease.
AalborgAges 18 years+ - NCT06956391RecruitingPhase 2
Ultra-low dose PET scan study using FDG
This study tests if a very low dose of a standard PET scan tracer (FDG) can produce clear images. It may help people who need a PET scan but are concerned about radiation exposure.
Englewood, New JerseyAges 18–120 - NCT07087106RecruitingPhase 4
Glucose use in the brain of people with MS
This study uses a special PET scan to see how the brain uses sugar (glucose) in people with multiple sclerosis (MS) compared to healthy volunteers. It may help researchers understand energy changes in the brain related to MS.
Boston, MassachusettsAges 18–70 - NCT01542879RecruitingPhase 1/Phase 2
MR scan for cancer staging without radiation in children and adults
This study tests a radiation-free whole-body MRI method to help doctors stage (find and measure) certain cancers. It may reduce radiation exposure compared with scans that use X-rays or radioactive tracers, while still checking how far cancer has spread.
Stanford, CaliforniaAges 6–40 - NCT07471776RecruitingPhase 2
Predicting ADC treatment response with PET scans in advanced breast cancer
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07479095Recruiting
Low-sugar, high-fat diet to improve PET scans for LPA lung cancer
This study tests whether a 7-day low-sugar, high-fat diet before a PET/CT scan can improve detection of a specific type of lung cancer called lepidic-predominant adenocarcinoma (LPA). If you have a suspicious lung nodule or biopsy-confirmed LPA, this diet may help the scan be more accurate.
Candiolo, Torino (TO)Ages 18 years+ - NCT06829043Enrolling by invitation
PET scan for uncertain thyroid nodules
This study uses a special PET scan (18F-FDG PET/CT) to get a clearer picture of thyroid nodules with uncertain biopsy results. The goal is to help doctors decide whether surgery is needed.
Bologna, ItalyAges 18 years+ - NCT06203119RecruitingPhase 1
Imaging test for triple-negative breast cancer
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
Beijing, Beijing MunicipalityAges 18–75 - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Birmingham, AlabamaAges Up to 12 months - NCT07021989RecruitingPhase 2
ctDNA-Guided Therapy for Relapsed Hodgkin Lymphoma
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
Davis, CaliforniaAges 18 years+ - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT06719856Recruiting
PET imaging study for multiple solid tumors
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
Beijing, Beijing MunicipalityAges 18–75 - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT06232889Recruiting
Imaging study to check liver tumor response to radiation treatment
This study uses special MRI scans and PET scans to see how liver tumors respond to a radiation treatment called radioembolization (SIRT). The goal is to improve how treatment response is measured in people with metastatic liver disease.
UtrechtAges 18 years+ - NCT07463807RecruitingPhase 1/Phase 2
Comparing two drug combinations for multiple myeloma that returned quickly
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07750470Recruiting
Pet scan to guide treatment for muscle-invasive bladder cancer
This study uses a special PET/CT scan to see how far your bladder cancer has spread. The results may help doctors plan the best treatment for you.
FerraraAges 18 years+ - NCT06647368Recruiting
Measuring brain sugar use with glucagon
This study tests a new way to measure how the brain uses sugar (glucose) to see if the hormone glucagon affects it. It may help researchers understand how certain hormones work in the body.
CopenhagenAges 25–70 - NCT06653452Recruiting
PET/MRI for rectal cancer treatment response
This study uses a special scan called PET/MRI to see how well treatment works for locally advanced rectal cancer before surgery. It may help doctors choose the best treatment plan for you.
Beijing, Beijing MunicipalityAges 18–75 - NCT05436093Recruiting
PET scan using a tumor-targeting probe in solid tumors
This trial studies whether a special PET scan probe that targets CLDN18.2 can help show solid tumors in the body. If you have a solid tumor that can be measured on scan, you may be invited to have imaging with the probe.
Beijing, Beijing MunicipalityAges 18–75 - NCT04702022Recruiting
Extra PET scan to check for silent kidney transplant rejection
This study tests whether an additional PET scan can help detect and guide treatment for “subclinical” (silent) rejection in people with kidney transplants. It may help doctors spot problems earlier and manage them more appropriately.
Liège, LiègeAges 18 years+ - NCT04143516RecruitingPhase 2/Phase 3
Test tissue testing right after liver tumor ablation
This study looks at liver metastases treated with a procedure that destroys tumors (ablation) and then checks tumor tissue right away. The team wants to see whether the tissue results can guide immediate retreatment to better control cancer in the liver.
New York, New YorkAges 18 years+
Common questions
- Are there clinical trials studying Fdg?
- Yes. Clin2 currently lists 153 recruiting studies that include Fdg, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Fdg trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Fdg an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Fdg or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.